Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cisco Systems Inc (CSCO) vs Sana Biotechnology Inc (SANA) Price & Performance

Cisco Systems IncTrade
Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

Cisco Systems Inc vs Sana Biotechnology Inc — how do they compare? Cisco Systems Inc trades at $123.7 (market cap $474.67B), while Sana Biotechnology Inc trades at $3.75 (market cap $1.13B). The key difference: Cisco Systems Inc is far larger — about 420.1× Sana Biotechnology Inc's market cap, and Cisco Systems Inc pays a 1.4% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.

CSCOSANA
Market Cap
$474.67B$1.13B
Volume
22,887,319
Sector
TechnologyHealth
52-Week High
$130.00$5.92
52-Week Low
$66.20$2.68
Enterprise Value
$489.33B$1.05B
Dividend Yield
1.4%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cisco Systems Inc

Cisco Systems (CSCO) trades at $122.57, up 0.94% today, near its recent highs driven by strong AI cybersecurity momentum. The stock shows bullish technical signals with moving averages supporting the uptrend, while RSI levels indicate potential overbought conditions. Fundamentally, CSCO reported revenue of $56.65B in 2025 with a net income margin of 19.69%, and has beaten EPS estimates for three consecutive quarters. Recent news highlights partnerships and product launches in AI security, fueling investor optimism.

CSCO's outlook is positive with a consensus price target of $133.25, implying ~9% upside, supported by 52% analyst buy ratings. Key opportunities include growth in AI-driven networking and security demand, but risks involve high valuation multiples (P/E 40.14) and competitive pressures in the tech sector. Investors should weigh strong cash flow generation against execution risks in a dynamic market.

Sana Biotechnology Inc

SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.

The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cisco Systems Inc

Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.

Read more on CSCO

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA